L-826,141

Known as: 4-(2-(3,4-bis-difluoromethoxyphenyl)-2-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-ethyl)-3-methylpyridine-1-oxide 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2008
01220022008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since the 1980s with asthma and chronic obstructive… (More)
Is this relevant?
2006
2006
Administration of phosphodiesterase 4 (PDE4) inhibitors suppresses the pathogenesis associated with experimental autoimmune… (More)
Is this relevant?
2006
2006
Phosphodiesterase-4 (PDE 4) enzyme inhibitors have been shown to have anti-inflammatory properties in various animal disease… (More)
Is this relevant?
2005
2005
The diseases of cystic fibrosis, chronic obstructive pulmonary disease (COPD), and chronic bronchitis are characterized by mucus… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
2004
2004
L-826,141 [4-(2-(3,4-bis-difluromethoxyphenyl)-2-(4-(1,1,1, 3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl)-3… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2002
2002
A detailed SAR study directed toward the optimization of pharmacokinetic parameters for analogues of L-791,943 is reported. The… (More)
Is this relevant?
2002
2002
Phosphodiesterase 4 (PDE4) inhibitors elevate cyclic adenosine 5'-monophosphate (cAMP), and this elevation has been shown to… (More)
Is this relevant?